Evidence map›Paper›PMID 40698280›Full record

ArticleWorld journal of orthopedics2025

Short-term survivorship of Truliant

Kirstin Jones, Amber M Muehlmann, Mark Musgrave, Colin T Penrose

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of orthopedics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kirstin JonesClinical Affairs, Exactech, Inc., Gainesville, FL 32653, United States.
Amber M MuehlmannClinical Affairs, Exactech, Inc., Gainesville, FL 32653, United States. amber.muehlmann@exac.com.
Mark MusgraveDepartment of Orthopaedics, Crystal Clinic Orthopaedic Center, Fairlawn, OH 44333, United States.
Colin T PenroseDepartment of Orthopaedics, Midwest Center for Joint Replacement, Indianapolis, IN 46241, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTruliant

aimTo analyze short-term survivorship of Truliant PS or CR total knee arthroplasty relative to non-Truliant PS or CR total knee arthroplasty.

methodsUtilizing data from the AJRR, a retrospective review was performed for subjects who underwent implantation of Truliant PS, Truliant CR, non-Truliant PS, and non-Truliant CR designs as of June 30, 2022. Survivorship and reasons for revision were compared statistically between Truliant PS

resultsTruliant PS survivorship was 97.95% at the four-year mark, while Truliant CR survivorship was 99.61% at the three-year mark. There were no significant differences in survivorship hazard ratios or reasons for revision for both Truliant groups

conclusionThis study demonstrates high survivorship for Truliant PS total knee arthroplasty out to four-years and Truliant CR total knee arthroplasty out to three-years of follow-up.

Indexed as

American Joint Replacement RegistryCumulative percent revisionRecallSurvivorshipTotal knee arthroplastyTreatment outcomeTruliant Cruciate RetainingTruliant® Posterior Stabilized

Identifiers

PMID40698280
PMCPMC12278276

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.